Coldrif cough syrup banned in Delhi

Written By :  Ruchika Sharma
Published On 2025-10-11 12:18 GMT   |   Update On 2025-10-11 12:18 GMT
Advertisement

New Delhi: In a move to safeguard public health, the Delhi government has banned the sale, purchase and distribution of Coldrif cough syrup after it was declared not of standard quality by the Government Analyst, Drug Testing Laboratory, Food and Drugs Administration, Madhya Pradesh.

"Coldrif Syrup (Paracetamol, Phenylephrine Hydrochloride, Chlorpheniramine Maleate Syrup), Batch Number: SR-13, Manufacturing date: May/2025, Expiry date: APR/2027, Manufacturer: 
Advertisement
Sresan Pharmaceutical Manufacturer, No 787, Bangalore Highways, Sunguvanchatram (Mathura), Kancheepuram Diastrict, 612106 of Tamil Nadu," the order stated.

The aforementioned drug formulation is reported to be adulterated, as it contains Diethylene Glycol (46.28% w/v), which makes the drug formulation injurious to health.

All stakeholders are directed to refrain from dealing in said cough syrup with immediate effect and not to indulge in purchase, sale and distribution of this cough syrup.
General public is also sensitized to abstain from using this cough syrup. 



 Read also: Contaminated Cough syrup tragedy: Sresen Pharma owner remanded in 10-day police custody

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News